Bryan, Garnier & Co’s Post

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, completed the merger with Applied Molecular Transport, a biopharmaceutical company. Financial terms were not disclosed. “The completion of this merger with Applied Molecular Transport represents a significant milestone and bolsters our confidence and excitement for the future of Cyclo Therapeutics. With the merger now closed and following our recent positive Type C meeting with the FDA, fundamentally the Company has never been stronger. Moving forward, we are focused on completing our Phase 3 study and executing on the regulatory submission process, assuming a successful outcome in our pivotal study. We remain dedicated to providing a much-needed treatment option for NPC patients," N. Scott Fine, Cyclo Therapeutics CEO. Applied Molecular Transport (led by Shawn Cross) was advised by MTS Health Partners, Wilson Sonsini Goodrich & Rosati (led by Ken Clark and Robert Ishii) and Wheelhouse Life Science Advisors (led by Alexandra Santos). Cyclo Therapeutics (led by N. Scott Fine) was advised by Fox Rothschild and Jenene Thomas Communications (led by Jenene Thomas). #MergersAcquisitionsDivestitures #Aviation #SPAC #PrivateEquity

Lilly to acquire biopharma firm Versanis for $1.9bn Versanis’ lead asset, bimagrumab, is currently being evaluated in the Phase IIb BELIEVE clinical trial. Eli Lilly and Company has signed an agreement for the acquisition of clinical-stage biopharmaceutical firm Versanis Bio in a $1.925bn deal. Versanis shareholders will receive the total amount in cash, including upfront development and sales-based milestone payments.  Established by Aditum Bio in 2021, Versanis develops new therapies for treating cardiometabolic ailments. Its lead asset, bimagrumab, is currently being evaluated in the Phase IIb BELIEVE clinical trial both as a monotherapy and along with semaglutide in adults who are obese or overweight. #pharmanews #mergerandacquisition #lifesciences #acquisition https://lnkd.in/dERhQ6rZ

Destiny Pharma plc (AIM:DEST, OTC:DTTYF), the clinical-stage #biotechnology company focusing on anti-infectives, said it will on finding a partner for XF-73 nasal and maximising its potential while developing its second key asset, NTCD-M3, in collaboration with Sebela Pharmaceuticals Inc. It provided an update on its strategy alongside its interim results. #DestinyPharma has a partnership deal for the latter with #SebelaPharmaceuticals worth up to £461 million ($570 million). Under the terms of this agreement, Sebela will finance the North American development and commercialisation of the C. difficile treatment. Destiny has received a £809,000 ($1 million) upfront payment from its partner, boosting cash and short-term deposits to £9.8 million as of June 30 and the company is funded through to the first quarter of 2025 following a £7.3 million fundraiser earlier this year. More at #Proactive #ProactiveInvestors #AIM #OTC #DEST #DTTYF http://ow.ly/Egsq104UOUS

Opening Day: Gilead-backed Kyverna overshoots raised IPO expectations Kyverna Therapeutics raised almost $320M in its initial public offering, which was priced above the marketed range. Backed by Gilead Sciences $GILD and Bain Capital Life Sciences Opportunities, the company's offering was the second largest for a drug developer this year. Meanwhile, Moderna $MRNA and Bayer $BAYRY-backed Metagenomi dropped over 30% in its Nasdaq debut on Friday.

Roche Makes Resounding Entry into Obesity Market! 💼💡 Roche, a global pharmaceutical giant, announces a resounding entry into the obesity market with a strategic move—acquiring Carmot Therapeutics, Inc. for a whopping upfront investment of $2.7 billion. Carmot, a biotech company, possesses a promising arsenal of injectable dual GLP-1/GIP receptor agonists and an oral GLP-1 drug currently advancing through clinical development. 💰 This strategic move by Roche involves a buyout offer to Carmot, originally poised for an initial public offering (IPO). The deal not only secures a significant upfront payment but also includes potential milestone payments of up to $400 million. #roche #CarmotTherapeutics #obesitytreatment #PharmaceuticalNews

Thoughts on this? >> J&J makes another I&I acquisition with $1.25B deal for Numab's Yellow Jersey >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #pharma #healthcare #pharmaceutical #biotech

🌐 Bryan, Garnier & Co acts as Joint Bookrunner to Swedish biopharmaceutical company Camurus on a Follow-on Offering of SEK 1,090m. Discover more here: https://lnkd.in/gSkjQZ6J 🔬 With its strong R&D expertise and proprietary FluidCrystal® technology, Camurus develops innovative, long-acting treatments for extended efficacy with a single injection. 🤝 Bryan Garnier remains committed to backing growth companies striving to develop and commercialize innovative and differentiated treatments. This marks the third fundraise for Nordic BioPharma over the past few months including Calliditas Therapeutics EUR 92m Debt Financing and Egetis Therapeutics AB's SEK 462m Combined Equity and Debt Offering, demonstrating once again our unique ability to raise capital for European healthcare companies in a highly competitive fundraising environment. 💰 Other recent deals with pioneers striving for a healthier future include Abivax’s structured debt financing transactions for up to EUR 150m followed by the company’s USD 236m Nasdaq IPO, Median Technologies’ EUR 21.6m Follow-on Offering & Convertible Bonds Issuance, and MedinCell’s EUR 25m Follow-on Offering. #Biotech #Biopharma #Chronic #Longacting #Camurus #BryanGarnier Pierre Kiecolt-Wahl, Vincent Meunier, Paul Lequeux, Gustaf Orsucci, Theodore de Charsonville, Pierre-Etienne Bénaich

Thoughts on this? >> J&J makes another I&I acquisition with $1.25B deal for Numab's Yellow Jersey >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #biotech #pharma #productmarketing #healthcare

Xenetic Biosciences Stock Rises By 32% In The Last 21 Sessions Framingham-based biopharmaceutical company Xenetic Biosciences (NASDAQ: XBIO) has seen its shares soar 32.37% over 21 trading sessions – an astounding increase at a time when NASDAQ shows only minor decline – making an unprecedented comeback after two consecutive periods of rapid expansion. An Unexpected Turnaround With shares soaring 58.3% since their 52-week high, Xenetic Biosciences’ […] https://lnkd.in/dNawJGS3 - Read more.

Arecor Therapeutics plc (AIM:AREC) has hinted that further deals are being penned for the second half of the year. In a business update which revealed that its interim results would come out in mid-September, the #biopharma firm suggested that further partnerships were being eyed following the two already sealed in 2023. “With further partnerships and collaborations expected, we are continuing towards our ambition of building a significant self-sustaining biopharmaceutical company,” #Arecor chief executive officer Sarah Howell said. AIM-listed #ArecorTherapeutics has already signed deals with a leading biopharmaceutical company and an existing top five #pharmaceuticals firm in the first half of the year, to develop biosimilar products and formulate existing assets respectively. More at #Proactive #ProactiveInvestors #AIM #AREC http://ow.ly/pxNj104OL47